Xiehe Group To Set Up Base In Shenzhen
This article was originally published in PharmAsia News
China's leading biopharmaceutical company, Shenyang Xiehe Group, has announced it will set up a wholly-owned subsidiary in Shenzhen High-Tech Industrial Park; it will also site its future R&D and international base in the city. Xiehe Group, a multinational conglomerate with 33 subsidiaries worldwide, integrates R&D, production and trading for health care items, biopharmaceuticals and other high-tech products. Its product value is expected to reach RMB 4 billion by 2010. The latest move is an important step in Xiehe Group's rapid growth as it will tap on Shenzhen's advantages in location and manufacturing to reap its R&D translational output as well as expand sales. The company has already established R&D centers in the U.S., Hong Kong and Shenyang. (Click here for more - Chinese Language)
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.